IONS Q3 2020 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$12B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$160M-4.7% YoY

Gross Profit

$157M98.1% margin

Operating Income

-$37M-22.8% margin

Net Income

-$24M-15.3% margin

EPS (Diluted)

$-0.22

QoQ Revenue Growth

+10.0%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$23M

Stock-Based Comp.

$46M

Balance Sheet

Total Assets

$3.1B

Total Liabilities

$1.5B

Stockholders' Equity

$1.4B

Cash & Equivalents

$633M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$160M	$168M	-4.7%
Gross Profit	$157M	$167M	-5.9%
Operating Income	-$37M	$3M	-1548.2%
Net Income	-$24M	$26M	-193.5%

Revenue Segments

Commercial

$95M37%

Spinraza Royalties

$74M29%

Research and Development Revenue Under Collaborative Agreements

$65M25%

Product

$19M7%

Licensing and Other Royalties

$2M1%